Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

“It’s quite a nifty device,” says Eric Topol, a cardiologist and chief academic officer at Scripps Health in San Diego who has been testing it. “Instead of doing a cardiogram, I just have them put their fingers on my phone. It’s really frugal and is a cost savings.”

The phone ECG, which AliveCor manufactures in China, is being studied in clinical trials in Oklahoma and at the University of Southern California and will need approval from the U.S. Food and Drug Administration before being sold in the United States. Albert says it will go on sale in Europe this fall.

At first, AliveCor planned to sell its device to doctors in poor countries. But after meeting with Apple executives about carrying his invention in their stores (discussions are ongoing), Albert believes he could have a consumer hit on his hands, or what he calls a “personal ECG acquisition device you could buy at Walmart.”

Topol says five to six million Americans suffer from the most common arrhythmia, atrial fibrillation. “It’s on my phone, but I’d like to get it on the patients’ phones, so they can send me their rhythm,” he says. “I could instantly tell them whether to go to the emergency room.”

Because so many people have smart phones—some 500,000 Android phones are activated daily worldwide—mobile technology may also upend the economics of some medical devices. Albert knows the low-priced iPhone ECG won’t generate the billion-dollar revenues big companies get from selling medical scanners, but he believes he “can make a little money from an awful lot of people and do really well.”

This August, AliveCor raised $3 million in financing with venture capital firms Burrill & Company, Qualcomm Ventures, and Oklahoma Life Sciences Fund. Following the investment, the company is valued at between $5 million and $10 million.

1 comment. Share your thoughts »

Credit: AliveCor
Video by AliveCor

Tagged: Business, Business Impact, The Era of E-Medicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me